LNPs-mRNA technology has been applied for expressing therapeutic antibodies, including those for the treatment of HER2-positive breast cancer [181], anti-human CD20 mAb (rituximab) for the treatment of non-Hodgkin’s lymphoma [217], and anti-PD-1 mAbs for the treatment of intestinal cancer [255]. Here, ERBB2 is linked to breast carcinoma.